Factors Contributing to the Clinical Effectiveness of the DPP-4 Inhibitor Sitagliptin in Patients With Type 2 Diabetes

Clinical Therapeutics
Shingo TakatoriHiroaki Araki

Abstract

Treatment with dipeptidyl peptidase 4 (DPP-4) inhibitors may have responders or nonresponders. However, agreement on the effects of patient background and/or contributory factors that have a negative effect on the efficacy of DPP-4 inhibitors is lacking. The aim of the present study was to investigate the effect of resistance factors on the clinical efficacy of sitagliptin (SITA) for patients with type 2 diabetes. We performed a retrospective study based on the medical records of patients who were treated with SITA alone (SITA-A; n = 16), a combination of a sulfonylurea (SU) without a change in dose and add-on SITA (SU + SITA; n = 29), SITA alone after the discontinuation of premedication with antidiabetic agents (SITA-AD; n = 18), or a combination of an SU with a dose reduction and SITA (L-SU + SITA; n = 17). Multivariate logistic regression analysis was employed to estimate the influence of resistance factors on hemoglobin (Hb) A1c lowering by SITA treatment for 3 months. The HbA1c levels were significantly lower after 3-month treatment with SITA-A (6.3% [0.2%]), SU + SITA (7.1% [0.2%]), and L-SU + SITA (6.6% [0.2%]), but not with SITA-AD (6.3% [0.2%]), than baseline levels before treatment. Multivariate logistic regression a...Continue Reading

References

Oct 1, 1994·Diabetes Research and Clinical Practice·T Kadowaki, H Yoshinaga
Nov 13, 2010·European Journal of Pharmacology·Alokesh DuttaroyBryan F Burkey
Jun 28, 2011·Lancet·Abd A TahraniAnthony H Barnett
Jan 5, 2012·Advances in Therapy·Matteo MonamiEdoardo Mannucci
Aug 12, 2014·Journal of Clinical Medicine Research·Erina ShigematsuYasuo Terauchi
May 28, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Jil MamzaIskandar Idris

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.